The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum
Open accessAbstract
The blood‐brain barrier (BBB) is important physiologically. Pathologically, BBB disruption has been implicated in a wide spectrum of neurological disorders including Parkinson’s disease (PD). Recent studies indicate that caffeine is protective against PD, but by poorly understood mechanisms. Using a MPTP neurotoxin model of PD we tested the hypothesis that the protective actions of caffeine were because of, at least in part, preventing MPTP‐induced BBB dysfunction. FVB mice were pre‐treated with caffeine (10 mg/kg, i.p.) or saline for 7 days prior to initiation of neurotoxin treatments; during the 7 days of neurotoxin treatment, caffeine or saline continued to be administered 10 min before each dose of MPTP (20 mg/kg, i.p.). Striatum (and for some studies hippocampus and cerebral cortex as well) were evaluated for BBB leakage, tight junction protein expression levels, integrity of dopaminergic neurons, and activation of astrocytes and microglia using immunostaining, immunoblotting and real‐time PCR techniques. We found that caffeine blocked MPTP‐induced decreases in numbers of tyrosine hydroxylase‐positive dopaminergic neurons, increases in leakage of Evan’s blue dye and FITC‐albumin in striatum but not in cerebral cortex or hippocampus, decreases in levels of the tight junction proteins occludin and ZO‐1, and increases in reactive gliosis. Our results suggest that caffeine might protect against PD and PD‐like features in animal models, in part, by stabilizing the BBB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Reduced expression of TJ proteins has also been shown in MPTP PD models (108).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [108]
The cited source says what the claim attributes to it.
In the citing paper
“compromised BBB integrity is also observed in rodent models of PD induced by systemic administration of MPTP (108, 680) or intrastriatal administration of 6-hydroxydopamine (6-OHDA) (95), including leakage of fluoresceinisothiocyanate (FITC)-labeled albumin (95, 108, 680), horseradish peroxidase (95), and Evan's blue (108) in the substantia nigra and striatum.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [108]
In the citing paper
“nigrostriatal vascular leakage has been reported in MPTP-treated mice [73]”
From Healthy Human Fecal Microbiota Transplantation into Mice Attenuates MPTP-Induced Neurotoxicity via AMPK/SOD2 Pathway (2023) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624
Nehlig, A., Daval, J., & Debry, G. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90012-b · Cited by 1,463
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Coffee and Health: A Review of Recent Human Research
Higdon, J. V., & Frei, B. (2006) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390500400009 · Cited by 1,090
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046
Cited by
Sorted by citations
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Adenosine receptors as drug targets — what are the challenges?
Chen, J., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 923
Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Cappelletti, S., Daria, P., Sani, G., & Aromatario, M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666141210215655 · Cited by 631
“In epidemiological reports, caffeine consumption was associated with a significantly lower risk of developing them [4, 11, 12, 120-122, 124].”
BackgroundAstrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease
Cabezas, R., Ávila, M. F., González, J., El-Bachá, R. D. S., Báez-Jurado, E., García‐Segura, L. M., Jurado-Coronel, J. C., Capani, F., Cardona‐Gómez, G. P., & Barreto, G. E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00211 · Cited by 481
Metadata
- Authors
- Chen, X., Lan, X., Roche, I., Liu, R., & Geiger, J. D.
- Affiliations
- University of North Dakota (US)
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2008-10-21
- Volume
- 107
- Issue
- 4
- Pages
- 1147-1157
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- PMC
- PMC3692355
- OpenAlex
- W2006684548
- Cited by
- 189
- References
- 71
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 12 · 2023: 18 · 2022: 11 · 2021: 14 · 2020: 13 · 2019: 11 · 2018: 7 · 2017: 9 · 2016: 13 · 2015: 11 · 2014: 10 · 2013: 10 · 2012: 9
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Center for Research Resources (P20RR17699, P20RR017699)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- caffeine, MPTP, blood-brain barrier dysfunction, Parkinson's disease, striatum, tight junction proteins, occludin, ZO-1, dopaminergic neurons, tyrosine hydroxylase, reactive gliosis, astrocytes, microglia, neuroprotection, neurotoxicity
- MeSH terms
- Central Nervous System Stimulants, Analysis of Variance, Animals, Blood-Brain Barrier, Caffeine, Corpus Striatum, Disease Models, Animal, Evans Blue, Gene Expression Regulation, Gliosis, Male, Membrane Proteins, Phosphoproteins, RNA, Messenger, Tyrosine 3-Monooxygenase, MPTP Poisoning, Matrix Metalloproteinase 9, Mice, Occludin, Zonula Occludens-1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
